255 related articles for article (PubMed ID: 27424664)
1. Ex vivo expanded regulatory T cells CD4
Lifshitz GV; Zhdanov DD; Lokhonina AV; Eliseeva DD; Lyssuck EY; Zavalishin IA; Bykovskaia SN
Autoimmunity; 2016 Sep; 49(6):388-396. PubMed ID: 27424664
[TBL] [Abstract][Full Text] [Related]
2. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
[TBL] [Abstract][Full Text] [Related]
3. T regulatory cells lacking CD25 are increased in MS during relapse.
Fransson M; Burman J; Lindqvist C; Atterby C; Fagius J; Loskog A
Autoimmunity; 2010 Dec; 43(8):590-7. PubMed ID: 20370571
[TBL] [Abstract][Full Text] [Related]
4. [The treatment by expanded ex vivo autologous regulatory T-cells CD4+CD25+FoxP3+CD127low restores the balance of immune system in patients with remitting-relapsing multiple sclerosis].
Eliseeva DD; Lifshitz GV; Lokhonina AV; Zhdanov DD; Zavalishin IA; Bykovskaia SN
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):54-62. PubMed ID: 27070362
[TBL] [Abstract][Full Text] [Related]
5. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
[TBL] [Abstract][Full Text] [Related]
6. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
7. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis.
McKay FC; Swain LI; Schibeci SD; Rubio JP; Kilpatrick TJ; Heard RN; Stewart GJ; Booth DR
J Autoimmun; 2008 Aug; 31(1):52-8. PubMed ID: 18406576
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.
Rossetti M; Spreafico R; Saidin S; Chua C; Moshref M; Leong JY; Tan YK; Thumboo J; van Loosdregt J; Albani S
J Immunol; 2015 Jan; 194(1):113-24. PubMed ID: 25452562
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease.
Su H; Ye DQ; Wang BL; Fang XH; Chen J; Wang Q; Li WX; Zhang N
Br J Dermatol; 2008 Jun; 158(6):1197-209. PubMed ID: 18410422
[TBL] [Abstract][Full Text] [Related]
10. Human CD4
Brown ME; Peters LD; Hanbali SR; Arnoletti JM; Sachs LK; Nguyen KQ; Carpenter EB; Seay HR; Fuhrman CA; Posgai AL; Shapiro MR; Brusko TM
Front Immunol; 2022; 13():873560. PubMed ID: 35693814
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients.
Frisullo G; Nociti V; Iorio R; Patanella AK; Caggiula M; Marti A; Sancricca C; Angelucci F; Mirabella M; Tonali PA; Batocchi AP
Immunology; 2009 Jul; 127(3):418-28. PubMed ID: 19016907
[TBL] [Abstract][Full Text] [Related]
12. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
[TBL] [Abstract][Full Text] [Related]
13. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.
Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB
Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and
Hui Z; Zhang J; Zheng Y; Yang L; Yu W; An Y; Wei F; Ren X
Front Immunol; 2021; 12():619932. PubMed ID: 33868236
[TBL] [Abstract][Full Text] [Related]
15. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity.
Ferreira RC; Simons HZ; Thompson WS; Rainbow DB; Yang X; Cutler AJ; Oliveira J; Castro Dopico X; Smyth DJ; Savinykh N; Mashar M; Vyse TJ; Dunger DB; Baxendale H; Chandra A; Wallace C; Todd JA; Wicker LS; Pekalski ML
J Autoimmun; 2017 Nov; 84():75-86. PubMed ID: 28747257
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.
Keever-Taylor CA; Browning MB; Johnson BD; Truitt RL; Bredeson CN; Behn B; Tsao A
Cytotherapy; 2007; 9(2):144-57. PubMed ID: 17453966
[TBL] [Abstract][Full Text] [Related]
17. FOXP3+ Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma japonicum: The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly.
Romano A; Hou X; Sertorio M; Dessein H; Cabantous S; Oliveira P; Li J; Oyegue S; Arnaud V; Luo X; Daujat-Chavanieu M; Mariani O; Sastre X; Dombey AM; He H; Li Y; Dessein A
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004306. PubMed ID: 26731721
[TBL] [Abstract][Full Text] [Related]
18. Decreased proportions of CD4 + IL17+/CD4 + CD25 + CD127- and CD4 + IL17+/CD4 + CD25 + CD127 - FoxP3+ T cells in children with autoimmune thyroid diseases (.).
Bossowski A; Moniuszko M; Idźkowska E; Grubczak K; Singh P; Bossowska A; Diana T; Kahaly GJ
Autoimmunity; 2016 Aug; 49(5):320-8. PubMed ID: 27206624
[TBL] [Abstract][Full Text] [Related]
19. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
[TBL] [Abstract][Full Text] [Related]
20. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
